Pharmacogenomics: the promise of personalized medicine. by Hood, Ernie
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Focus | Pharmacogenomics
Imagine being able to
walk into your doctor’s office and pres-
ent a “smart card” encoded either with the
sequence of your genome itself or with an access
code granting permission to log on to a secure data-
base containing your genomic information. Armed with
a complete and accurate understanding of your unique
genome, your physician would be able to prescribe the right
drug in the right dosage at the right time to effectively treat
your condition, with little or no concern that the therapy
won’t work or that you will suffer adverse side effects.
That day of truly personalized medicine is still just a gleam in the eyes of the sci-
entists engaged in pharmacogenomics, but they are unanimous in their belief that
it is achievable and that it will arrive. 
Just as genomics is the study of the entire genome while genetics is the study
of individual genes, pharmacogenomics looks at inheritable response to drugs
over the entire genome while pharmacogenetics identifies interactions between
drugs and individual genes. Pharmacogenomics seeks to uncover significant asso-
ciations between genomic patterns and clinical outcomes—correlations that pro-
duce useful predictive knowledge, allowing clinical treatment decision making to
be based upon more rational criteria than today’s probabilistic approach, which is
largely based upon educated guesswork. 
Drug treatment is fundamentally a well-controlled environmental challenge to
the individual, says Gualberto Ruaño, vice chairman and chief scientific officer of
Genaissance Pharmaceuticals in New Haven, Connecticut. “What we learn from
pharmacogenomics will also apply to envirogenomics,” he says, “as relates to
exposures to other challenges relevant to environmental health, such as pollution,
toxins, radiation, heat and cold, and even food.”
Although the enormous variability in people’s responses to drugs cannot be
attributed solely to their genotype, scientists believe that by understanding the
genetic underpinnings of how people absorb and metabolize drugs, they will
eventually quantify a great deal of that variability and be able to tailor therapies
accordingly in order to optimize treatment and avoid adverse effects. The influ-
ential physician Sir William Osler summarized the problem aptly in 1892: “If it
were not for the great variability among individuals, medicine might as well be a
science and not an art.” By solving much of the riddle of variability, pharma-
cogenomics may contribute to swinging the balance of medicine much further
toward science.
Why Pharmacogenomics?
If pharmacogenomics can do nothing more than help reduce the frequency of
adverse drug reactions (ADRs), it will have a tremendously positive impact on
morbidity and mortality. According to a landmark meta-analysis appearing in
the 15 April 1998 issue of the Journal of the American Medical Association, more
than 2.2 million hospitalized patients in the United States had serious ADRs in
1994, resulting in more than 100,000 deaths and making ADRs the fifth
leading cause of death in the nation. If a patient is genetically predisposed
to be a poor metabolizer of a particular drug or class of drugs, when that
drug is administered, even at normal dosages, amounts of the agent
retained in the system can quickly build to toxic concentrations,
leading to an ADR. 
Experts believe that ADRs are likely to be the first
area in which pharmacogenomics will benefit
patients. “The first advancement that’s already taking place
is that we will understand
better what people will
have a high drug level if
we give them a drug, ver-
sus a low drug level,” says
David Hein, Peter K.
Knoefel Professor and
Chairman of the Depart-
ment of Pharmacology
and Toxicology at the
University of Louisville.
Today’s trial-and-error,
one-drug-fits-all approach
to prescribing also means
that all too often a medi-
cine is ineffective, resulting
in wasted treatment time,
high health care and drug
costs, and, most importantly,
therapeutic failures. Pharmacogenomic
analysis can help identify patients who are
abnormally high metabolizers of certain
drugs. These people metabolize so much of
the agent that it passes through their system
without its intended effect. 
Like ADRs, ineffective drug therapy is a
widespread problem in clinical practice, and
it can have serious consequences, particular-
ly in the treatment of diseases in which
delays in determining effective therapy can
be disastrous, such as psychiatric disorders,
hypertension, and cancer. “There’s an ele-
ment of time in which patients are taking a
drug, and it takes some period of time for
that drug to become efficacious,” says
Michael Murphy, president and chief execu-
tive officer of Gentris, a Morrisville, North
Carolina, company offering pharmacoge-
netic laboratory services and diagnostic
tests. “Depending on the illness, that could
be pretty devastating, to be taking a drug
and waiting for some-
thing to happen, only to
find out that it doesn’t.” 
Penelope Manasco,
chief medical officer and
executive vice president
of First Genetic Trust, a
Deerfield, Illinois–based
company involved with
genetic data handling and
bioinformatics, agrees.
“Now most drugs are
between thirty and fifty
percent effective,” she
says. “That’s a really big
deal when it’s something
like a drug for depression.
It  can take people six
months to a year to get on the
right drug. And with pharma-
cogenomics, they’ll be able to have a test
that will say instead of having a thirty or
forty percent chance, they’ll have a seventy
or eighty percent chance that this medicine
will work.”
Scientists in pursuit of personalized
medicine believe that although pharmacoge-
nomics has already begun reaping benefits,
the field is still in its infancy, and change will
come gradually. “In the short term,” says
Hein, “we’re going to have less drug toxicity.
In the long term, we’re going to have much
better drug effectiveness.” 
Roger Ulrich, senior scientific director of
Rosetta Inpharmatics, a subsidiary of Merck
engaged in the application of pharmacoge-
nomics to the drug discovery process, feels
that it’s going to be a while until there’s a
practical, everyday application of pharma-
cogenomics approaches. Clinical trial data
already show there’s variation in response for
almost any agent, he says. “I think over the
next several years, we’ll understand why we
see variation in response. . . . And there will
be a sort of gradual assimilation of that data
into practice,” he adds. “I don’t think any of
us are going to wake up one morning and
go, ‘Wow, we’ve finally entered the era of
individualized medicine.’ However, within
research, the impact of pharmacogenomics
has already been positively felt, from the way
we discover and validate therapeutic targets
to the way we explore drug safety and design
clinical trials.” 
Rochelle Long, chief of the Pharma-
cological and Physiological Sciences
Branch of the National Institute of
General Medical Sciences (NIGMS), fore-
sees a similar pattern of steady develop-
ment in knowledge and implementation
of pharmacogenomics: “I think progress
will be incremental. . . . Within the next
one to five years, we’re simply going to
understand enough to, in a systematic
way, better use some of the drugs that are
already on the market.” Within 5–10 years
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Alkaptonuria
In 1902, while investigating
alkaptonuria, a rare inherited enzyme
deficiency that results in joint disease,
physician Archibald Garrod suggested
that genetic differences in metabo-
lism may be responsible for
adverse drug reactions.
Favism
The advice of Greek
philosopher Pythagoras
to avoid fava beans was
prescient, as later scien-
tists discovered a genetic
deficiency that causes
acute hemolytic anemia 
in certain people who
consume the legumes. Environmental Health Perspectives • VOLUME 111 | NUMBER 11 | August 2003  3
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after that, she says,
there should be a little
more progress in the area
not of drug metabolism, but
of variants in target receptors
themselves; within the period after that,
people are going to start better under-
standing the genetic basis of complex dis-
eases such as hypertension, and drugs will
be designed based on that understanding.
Pharmacogenetics Begat
Pharmacogenomics
Pharmacogenomics may be in its infancy,
having only recently come into its own on
the heels of the advances in knowledge,
method, and technologies generated by the
Human Genome Project. But the discipline
has deeper roots in pharmacogenetics, a
field of study that has been formally recog-
nized for more than 50 years, and that exist-
ed in practice much earlier. 
“Avoid fava beans.” So Greek philoso-
pher Pythagoras instructed his followers
in the sixth century B.C., supposedly
because he noticed that consumption of
fava beans made some people sick.
Pythagoras may or may not deserve to be
called the father of pharmacogenetics, but
his observation was on the money—in the
twentieth century, scientists discovered
that ingestion of uncooked fava beans can
cause acute hemolytic anemia, a serious
red blood cell disorder, in certain popula-
tions. In the 1950s, it emerged that an
inherited deficiency of glucose-6-phos-
phate dehydrogenase, a red blood cell
enzyme, caused this reaction, known as
favism. Today, this enzyme deficiency is
known to be a relatively common disorder
among certain populations, and has sub-
sequently been linked to sensitivity to a
variety of drugs, particularly antimalarial
agents and sulfa antibiotics. 
The emergence of pharmacogenetics in
the twentieth century followed a path
forged by advances in molecular biology
and genetics. In the mid–nineteenth cen-
tury, scientists learned that ingested sub-
stances were excreted in different forms,
establishing the concept of metabolism. In
1902, the physician Sir Archibald Garrod,
investigating alkaptonuria, a rare inherited
enzyme deficiency, suggested that enzymes
were  important in the detoxification of
foreign substances, and that genetically
determined differences in the operation of
enzymes (characterized by Garrod as
“inborn errors of metabolism”) could be
responsible for ADRs. The year 1931 saw
what is regarded as the first pharmacoge-
netic findings, when chemist Arthur L.
Fox reported on “taste blindness,” an
inherited difference in subjects’ ability to
taste phenylthiocarbamide. 
Before technology allowed the study of
individual genetic variation, the field con-
centrated on identifying racial and ethnic
variations in response to drugs. Most
notable among several landmark studies,
perhaps, was University of Toronto profes-
sor emeritus Werner Kalow’s investigation
in the 1950s of the occurrence of prolonged
paralysis and rare, unexplained deaths in
surgical patients receiving succinylcholine,
a neuromuscular blocker tolerated well by
most patients. Kalow discovered that a
genetically based deficiency in the metabo-
lizing enzyme pseudocholinesterase was
responsible, and proceed-
ed to describe the popula-
tion incidence of the various
alleles responsible for the defi-
ciency. Similar studies confirmed the
genetic basis of the variability, seen in
response to a wide variety of drugs.
As the wider fields of genetics and
molecular biology progressed, so did
pharmacogenetics. Now essentially folded
into the burgeoning science of pharma-
cogenomics, the discoveries that have
emerged from the progenitor field are
today available and in use in the diagnos-
tic arena, helping to screen patients who
fall into broad populations that, due to
their metabolic genotypes, should not
receive specific drugs. As Murphy states it,
“The reality is that for a lot of genes that
we’ve known about for the last twenty or
thirty years, the need is to have a clinical
test that defines two or three patient pop-
ulations [i.e., normal, high, and low
metabolizers], and we can do that now.”
SNPs and Haplotypes
The remarkable innovations that led to
the sequencing of the human genome
spawned a great leap forward, as pharma-
cogenetics spawned pharmacogenomics.
Technological breakthroughs such as
polymerase chain reaction, high-through-
put robotic sequencing, and DNA
microarrays, as well as simultaneous
advances in bioinformatics—which
brought the ability to mine the mountains
of data produced for nuggets of useful
knowledge—have allowed the field to
move forward quickly, as the genome
begins to reveal some of its age-old
secrets. Perhaps most significant to phar-
macogenomics has been the relatively
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Taste Blindness
In 1931, in what is regarded as the first
pharmacogenetic findings, chemist
Arthur L. Fox reported on “taste blind-
ness,” an inherited difference in
subjects’ ability to taste phenylthio-
carbamide.recent discovery of two
related genetic phenom-
ena—single-nucleotide
polymorphisms, or SNPs,
and haplotypes. They have
transformed the notion of personalized
medicine from fond fantasy to realistic goal. 
SNPs are single-letter variations in
DNA sequence that happen in at least 1%
of the population (lower-frequency varia-
tions are considered to be mutations).
They occur every 100–300 bases along the
3 billion base pairs making up the human
genome. By collecting and analyzing the
DNA of a diverse group of many individ-
uals, researchers are working toward iden-
tifying SNPs that are relevant markers of
drug response and disease susceptibility,
an endeavor they hope will ultimately
yield diagnostic tests and targeted drugs
based on genotype. 
The discovery that SNPs tend to occur
in patterns or blocks called haplotypes
may help speed the process of squeezing
clinically relevant information out of the
human genome. Haplotypes are inherited
groups of SNPs that occur within a
defined region of the chromosome, and
some of them may influence drug response
more than individual SNPs do. Some
experts believe that identifying haplotypes
of interest will yield more useful biomark-
ers of response by accounting for genomic
variation in the multiple genes often
involved in drug response. 
Genaissance Pharmaceuticals is one
biotechnology company banking heavily
on the value of haplotypes. “The haplotype
is composed of multiple SNPs, but it has
the advantage and the power that it has the
SNPs grouped into an alignment as to how
they occur in the chromosome and code
for different versions of the gene,” says
Ruaño. “Because of that resolution and
symmetry with the physiology and the
function, the haplotype is therefore a much
higher-resolution technique for looking at
genetic associations.” 
Murphy agrees to a point: “Sometimes
when we don’t know how mutations segre-
gate—that is, the pattern of how they fall
on the two copies of every gene that we get
from our parents—then we have to do hap-
lotyping. Where we do know [how muta-
tions segregate] . . . haplotyping would just
be overkill. So sometimes it’s needed, but
sometimes it’s not, and you just have to
take it on a case-by-case basis. Whether it
be SNP analysis or haplotyping, the most
important thing is that we can predict phe-
notype, or clinical outcome.”
Pharmacogenomics Initiatives
The rapid development of pharmacoge-
nomics has led to an encouraging amount
of scientific cooperation and collaboration
among government, industry, and acade-
mia. “There’s always some competition, but
actually I think people have been very col-
laborative,” says Manasco. “One of the key
things that’s going to be needed is more
money for this translational research . . . so
that the people who actually win are the
patients.” 
Ulrich voices similar sentiments. “It’s a
whole different approach to science, this
large-scale international consortium
approach,” he says. “There are pockets of
opportunity for each individually, but
because of the size of the
challenge, it’s going to take
a continued joint effort.” 
Large-scale collaborative
initiatives are making significant
contributions to the effort to eventually bring
the benefits of pharmacogenomics to the bed-
side. One such effort, the Pharmacogenetics
Research Network (PGRN), was established
in 2000 and currently funds 13 academic
research groups conducting basic research
describing pharmacogenetic phenotypes and
relating them to genetic and genomic infor-
mation. The PGRN is spearheaded by the
NIGMS, with the participation of the
National Cancer Institute, the National
Heart, Lung, and Blood Institute, the
National Human Genome Research Institute,
the National Library of Medicine, and the
NIEHS, making it a true trans-NIH effort. 
Long, the NIH program director for
the PGRN project, says the network
stresses high-quality research. “We want
interdisciplinary groups of researchers,”
she says, “who are coming together and
putting their brains and expertise together
to design the very best pharmacogenetic
projects, and then execute them, collect
the data, and put it in the database.” 
The database she refers to is the
Pharmacogenetics and Pharmacogeno-
mics Knowledge Base, or PharmGKB
(http://www.pharmgkb.org/), developed
by and based at the PGRN grantee group
at Stanford University. Long emphasizes
that although the data from PGRN mem-
bers are the core resource of the
PharmGKB, the database is open to access
and contributions by one and all. “These
data are all made public: the tools and
resources that [PGRN members are] gener-
ating, primers, or any sort of chips they’re
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Succinylcholine-Induced Paralysis
In one of the first descriptions of the
genetic basis of variability in drug
response, professor Werner Kalow report-
ed that paralysis after receiving the 
neuromuscular blocker succinylcholine
was due to a genetically based 
deficiency in pseudocholinesterase.developing, or reagents,” Long says. “The
intention also is to make [these resources]
available to the community at large. . . . So
we’re impacting all pharmacogenetics
researchers, whether or not they’re presently a
member of this network.” [For more infor-
mation on both of these efforts, see “The
Pharmacogenetics Research Network and the
Pharmacogenetics and Pharmacogenomics
Knowledge Base,” p. A575 this issue.]
In  1999, the International Life
Sciences Institute Committee on the
Application of Genomics in Mechanism
Based Risk Assessment was formed. This
international consortium, with participants
from industry, government, and academia,
evaluates experimental methodologies for
measuring alterations in gene expression,
and, in collaboration with the European
Bioinformatics Institute, is building an
extensive database of microarray assays and
analyses, which is scheduled to be made
public in 2004. A March 2003 white paper
reporting on the committee’s status and
recent findings is publicly available at
http://rsi.ilsi.org/file/ACF539D.pdf.
Also formed in 1999, The SNP Con-
sortium (TSC) is a nonprofit collaborative
effort among several major pharmaceutical
companies, technological companies, and
academic research centers, along with the
Wellcome Trust, with the target of identi-
fying 300,000 SNPs of biomedical interest.
The discovery phase of the project, which
is now essentially com-
plete, in the end identified
1.8 million SNPs. The
group viewed this high-
density SNP map, which
is publicly available online
at  http://snp.cshl.org/,
as an important resource
for defining haplotype
variation across the ge-
nome, and a rich source of
new genomic information
about disease susceptibili-
ty, drug response, and
novel therapeutic targets. 
The SNPs identified
by  TSC contributed a
major source of data for
another extensive public library
of variations, this one hosted by the
National Center for Biotechnology Inform-
ation. This library, dbSNP, located online
at  http://www.ncbi.nlm.nih.gov/SNP/,
now contains more than 4.1 million
human SNPs, a significant portion of the
estimated 10 million common SNPs in the
human genome. 
More  recently, a $100 million pub-
lic–private research consortium called the
International HapMap Project was
launched in October 2002. Expected to
take three years to complete, the HapMap
will map the haplotypes in the human
genome, obviating the need to study all
10 million SNPs. With
the abundant informa-
tion embedded in haplo-
types and their variation
across populations, the
HapMap is expected to
be a powerful new tool
for researchers to con-
duct association studies.
This will allow them to
precisely identify signifi-
cant genetic variations
in disease susceptibility,
drug response, and even
infectious disease resist-
ance and longevity [also
see “HapMap: Building a
Database with Blocks.”
EHP 111(1T):A16 (2003)].
Pharmacogenomics and the
Pharmaceutical Industry
The pharmaceutical industry has seen the
future. In a 9 April 2003 presentation to a
U.S. Food and Drug Administration (FDA)
Science Board Advisory Committee meet-
ing, Brian Spear, director of pharmacoge-
nomics at Abbott Laboratories in Abbott
Park, Illinois, put it succinctly: “[Pharmaco-
genomics] is not something that a company
here and a company there have taken a
chance on. This is now a standard part of
the drug discovery and development process
in every one of the drug discovery and
research companies.”
The industry’s avid pursuit of pharma-
cogenomics, as evidenced by a recent spate
of acquisitions of pharmacogenomically ori-
ented biotechnology firms by the major
pharmaceutical companies, runs the gamut
from drug discovery to enhancing the safety
and efficacy of drugs that have been on the
Environmental Health Perspectives • VOLUME 111 | NUMBER 11 | August 2003  5
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Gene Technologies
Breakthroughs such as polymerase
chain reaction, high-throughput
robotic sequencing, bioinformatics,
and DNA microarrays have enabled
great leaps forward in the ability
to quantify and analyze
genetic data.
SNPs and Haplotypes
The analysis of two 
genetic phenomena—SNPs
(single-letter variations in
DNA) and the patterns
that they occur in, known
as haplotypes—allows
researchers to identify
biomarkers of drug
response and disease 
susceptibility.6 VOLUME 111 | NUMBER 11 | August 2003 • Environmental Health Perspectives
market for many years.
Just as the days of the
one-drug-fits-all treat-
ment approach may be
numbered, so too may
be those of the present
pharmaceutical industry
business model, which
relies heavily on the
periodic introduction of
blockbuster drugs (typi-
cally defined as products
with annual revenues in
excess of $1 billion) to
generate profits and fund
research and develop-
ment. The hope is that
the application of phar-
macogenomics and other
genomics technologies will
enable a new paradigm to
emerge, with lower development
costs, fewer candidate drug failures, revital-
ized existing products, the possible resuscita-
tion of withdrawn drugs, and a “portfolio”
approach to the introduction of new agents,
with drugs available in different formulations
to maximize safety and efficacy in specific
phenotypic populations.
According to A Revolution in R&D: How
Genomics and Genetics Are Transforming the
Biopharmaceutical Industry, a 2001 report by
The Boston Consulting Group, it currently
takes on average $880 million and 15 years
to bring a new drug to market. Failed candi-
date compounds represent a large propor-
tion of that development cost—right now,
only about 10% of compounds that enter
clinical development make it to the market-
place. The Boston Consulting Group esti-
mates that the effective application of
genomics technologies could reduce that
staggering investment by
as much as $300 million
and two years. 
Ulrich is optimistic
that pharmacogenomics
can play a major role in
increasing drug develop-
ment productivity. “The
real cost savings will be
that we have fewer failures
going into development,”
he says, adding, “Making
better choices is really
what it’s all about. In the
end, you might develop
just as many compounds,
but you’re going to have
more successes. You’ll
spend just as much money,
but you’ll get a greater return
on investment.” 
Ruaño anticipates that pharma-
cogenomics will contribute to all pharma-
ceutical products, from new candidates to
old warhorses. “The bottom line is that if
you match the chemical and pharmacologi-
cal properties of the drug to a target popu-
lation that benefits from that drug, you have
a new product,” he says. “I believe that can
be applied to old, new, and in-the-middle
drugs, in-the-middle being the ones that are
in clinical design and trials, the new being
early-discovery ones from genomic targets,
and the old, the ones that we have already
on the market.”
Many pharmaceutical companies are
already using pharmacogenomics to screen
participants in clinical trials. Murphy,
whose company provides such screening
services to the major pharmaceutical com-
panies, has seen this concept evolve from
novel idea to accepted necessity. “We have a
number of clients now who routinely
screen every single volunteer at Phase I for
the important drug metabolism genes,” he
says. “That’s a big paradigm shift. And then
they consider those same inclusion/exclu-
sion criteria, or stratification as they call it,
as they continue to develop that same drug
in Phases II through IV.”
The FDA appears to be solidly on
board the pharmacogenomics bandwagon
as well. The agency has reportedly been
working hard recently to acquire the nec-
essary in-house expertise to facilitate the
submission, interpretation, and imple-
mentation of pharmacogenomics data.
“These studies are being widely done, and
they may have tremendous progress,” said
Janet Woodcock, director of the FDA
Center for Drug Evaluation and Research,
at the agency’s 9 April 2003 Science Board
Advisory Committee meeting. “We need
to find a way to get the information in,
develop our policies, develop a regulatory
framework, . . . and help to move this field
Focus | Pharmacogenomics
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Pharmacogenetics Research
Network
Formed in 2000 by the NIH, this 
network funds 13 academic research
groups to describe pharmacogenetic
phenotypes and relate them to
genetic and genomic information.
The SNP Consortium
and HapMap
A nonprofit collaborative
organized in 1999, The
SNP Consortium has iden-
tified 1.8 million SNPs of
biomedical interest and
arranged them in a pub-
licly available high-density
SNP map. In 2002, the
private–public $100 million
HapMap research initiative
was launched to map all
of the haplotypes in the
human genome.Environmental Health Perspectives • VOLUME 111 | NUMBER 11 | August 2003  7
along.” Later this year,
the FDA is expected to
issue guidelines designed
to enable the free exchange
of information between the
industry and its regulators, with the goal
of bringing the benefits of pharmacoge-
nomics to the bedside as soon as possible. 
Applied Pharmacogenetics 
Most of the promise of pharmacogenomics
remains to be fulfilled. However, the concept
of using known genetic associations to pre-
vent patients from taking drugs that would
likely be ineffective or harmful is already
available and used in clinical practice in cer-
tain specific arenas, thanks mainly to the
steady progress made in pharmacogenetics
over the past several decades. 
Cancer therapy today includes two
shining examples of applied pharmacoge-
netics. First, there is now a commercially
available diagnostic test measuring a
patient’s ability to produce the metabolic
enzyme thiopurine S-methyltransferase
(TPMT), which is essential for the metab-
olism of thiopurine medications used to
treat acute lymphoblastic leukemia (ALL),
the most common form of childhood can-
cer. Genetic testing gives clinicians the
ability to classify ALL patients according to
their TPMT genotype, which allows opti-
mized dosing. Doses in patients with alle-
les rendering them deficient in TPMT
(who are thus less tolerant of thiopurine
medications) are reduced by as much as
95%. This means TPMT-deficient patients
can tolerate the drug, yet enough is still
metabolized to retain efficacy.
Second, the breast cancer drug
trastuzumab (trade name Herceptin), which
is marketed in tandem with a diagnostic
test, is often cited as an early indicator of the
value of the concept. Trastuzumab is effec-
tive only sin the 25–30% of breast cancer
patients whose tumors overexpress the
human epidermal growth factor receptor
(HER2) protein. The drug was developed
specifically to exploit that characteristic; it
binds to HER2, which slows tumor growth.
The diagnostic test measures HER2 expres-
sion in the tumor and is thus predictive of
the potential efficacy of the drug; patients
who do not overexpress HER2 are not given
the drug, because it will not work. 
This is a unique combination today.
But such diagnostic–agent pairings will
become more commonplace as pharma-
cogenomics progresses and strides are
made in disease genetics, in which a variety
of diseases (particularly cancer) are being
genetically subclassified, often significantly
redefining treatment strategies. 
An intermediate step toward such pair-
ings is illustrated by work being done with
the cytochrome P450 (CYP450) family of
enzymes, which is responsible for a large
segment of human drug metabolism. It is
the metabolic pathway of choice for about
60% of the drugs on the market today. It
has also been the focus of a great deal of
research attention through the years, and
the numerous CYP450 subtypes are well
characterized, as are the important pheno-
types of variation in response. Several com-
panies now offer CYP450 genotyping tests
to the pharmaceutical industry for clinical
trial subject inclusion/exclusion based upon
metabolic profile, and now such tests are
making their way into the
clinical diagnostic market-
place. Gentris, for example,
soon expects to market five
kits to physicians for pharmacoge-
netic testing of their patients. Genelex
Corporation of Seattle, Washington, has
taken the concept one step further, market-
ing tests directly to the public for three of
the major CYP450 pathways—CYP2D6,
CYP2C9, and CYP2C19. Once a consumer
has placed an order for the test, Genelex
sends them a blood collection kit, and the
consumer either sees their own doctor or
Genelex will refer them to a phlebotomist in
their area.
Pharmacogenomic tests appear to be
just over the horizon. In March 2003, at
the 52nd Annual Scientific Session of the
American College of Cardiology, Gen-
aissance presented results from its
STRENGTH (Statin Response Examined
by  Genetic Haplotype Markers) prospec-
tive clinical study, which showed that hap-
lotype variations are associated with
response to treatment with the statin class
of cholesterol-lowering drugs. The associa-
tions discovered in the study were strongly
predictive of efficacy. Genaissance plans to
eventually develop the information into a
point-of-care diagnostic test that will help
physicians choose the safest and most effec-
tive drug for individual patients, maximiz-
ing the prevention of cardiovascular disease
afforded by the statins. The company has
performed similar studies of response to
asthma drugs, and other researchers in
industry, academia, and government are
making substantial progress in establishing
variability associations for drugs used to treat
hypertension, depression, HIV, cancer, and
several other conditions whose patients
Focus | Pharmacogenomics
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Clinical Trials
Pharmacogenomics is already being
used to screen participants for drug
clinical trials, thereby saving money,
time, and effort.8 VOLUME 111 | NUMBER 11 | August 2003 • Environmental Health Perspectives
stand to benefit from
optimized prescribing.
Ethical Concerns
On one level, the ethical
issues involved with pharma-
cogenomics are similar to those raised by
genomics in general—broad concerns
about research integrity, privacy, confi-
dentiality, informed consent, the specter
of genetic discrimination or stigmatiza-
tion, and access to information or to spe-
cialized care. “There are certainly inher-
ent problems that will not go away with
pharmacogenomics research,” says Patrick
Terry, president of PXE International, a
patient advocacy and research support
group for victims of pseudoxanthoma
elasticum, a rare genetic disorder that
affects connective tissues. “They’re cer-
tainly not new and different for pharma-
cogenomics research. Privacy, confiden-
tiality, and misuse or misappropriation of
data were the same twenty years ago as
they are today.” 
Alan Combs, Johnson & Johnson
Professor of Pharmacology at the University
of Texas at Austin, is excited about the
potential benefits of pharmacogenomics but
worried about how people will apply the sci-
ence. “It’s the goose that laid the golden egg
in potential,” he says, “but you have to be
very  careful with that goose. I don’t see
where the line is going to be drawn between
using it for good and abusing it. The
advances are inevitable, and they’re neu-
tral—it’s how we use them.”
Many observers, however, feel that the
ethical issues specific to pharmacogenomics
are actually somewhat less problematic
than the ethical lightning rods attached to
genetics or even to pharmacogenetics. One
crucial difference lies in the nature of the
information itself, which typically applies
to individual patients as opposed to larger
groups. Says Combs, “The beneficial deci-
sions you make on an individual basis are
almost always good. The decisions you
make based on populations are not nearly
so likely to be good.” 
Ulrich draws another ethical distinc-
tion between pharmacogenomics and
pharmacogenetics. “When you evaluate
phenotype and use phenotype to stratify a
patient population, it isn’t necessarily
linked to genotype, so you haven’t actually
put a label on the individual,” he says. “So
I think there’s plenty of room for pharma-
cogenomics without the ethical concerns
that go along with pharmacogenetics;
there’s a difference.” 
Ruaño agrees that the ethical issues
connected to pharmacogenomics are per-
haps less urgent. “The reason is that the
core of pharmacogenomics is pharmaceu-
tical intervention,” he says. “The fact that
we’re talking about genomics that has a
‘pharmaco-’ attached to it means that the
purpose is treatment, not primarily diag-
nosis of the disease.”
Of course, such distinctions could be
lost on patients without the appropriate
educational efforts and informed-consent
safeguards in place, in both research and
clinical settings. “I don’t know why any-
body wouldn’t want to know whether
what their doctor is prescribing will actu-
ally work for them,” says Carol Isaacson
Barash, founder and
principal of Genet-
ics, Ethics & Policy
Consulting, a Boston
company that consults to
medical and technology
groups. “But I think the public is still a
bit fearful of what genetic testing is and
what it isn’t, and how it could help and
how it could hurt them.” 
Terry voices similar concerns: “I think
there are certainly misunderstandings in
both the professional and patient commu-
nities, both fears and emotional issues on
these technologies that may be real or may
not be real, but that nonetheless touch on
some kind of organic or intuitive fear of
the technology and what’s being sold.”
Today, pharmacogenomics is still pre-
dominantly a research endeavor, and the
nature of informed consent is presently
the most prominent ethical consideration
for investigators. Manasco, whose compa-
ny offers itself as a repository for and gate-
keeper of access to patients’ genetic data,
sees an evolution in the concept of
informed consent. “It’s one of the big
issues, making sure that people under-
stand what their samples will be used for,”
she says. “We’re actually at a turning point
from when people gave consent for what-
ever researchers wanted to do with their
samples, to the point now where the ethics
community is becoming more restrictive
in what they will allow, because in fact you
truly cannot give informed consent if
you’re saying, ‘You can use my sample for
whatever research you want in the
future.’” She adds, “I expect over time
multiple approaches will be used to make
sure people are really informed, that they
don’t just get a five-page sheet; . . . that
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Cancer Therapies
Screening a patient’s ability to produce the
enzyme TPMT helps doctors determine optimal
doses of medicines used to treat acute lym-
phoblastic leukemia in children. And the breast
cancer drug trastuzumab is now marketed with
a test to measure overexpression of the drug’s 
target protein, HER2. The drug is ineffective 
in women who do not overexpress HER2.Environmental Health Perspectives • VOLUME 111 | NUMBER 11 | August 2003  9
they really understand what they’re being
involved in.” 
Achieving the appropriate level of
informed consent could prove to be a
major challenge, as participants will need
to comprehend that their DNA could be
used for multiple experiments over a long
period of time, and that in many cases,
their samples will not be anonymous. In
many pharmacogenomics studies, anony-
mization of samples defeats the purpose
of drawing associations between drug
response and populations. 
On  the other hand, participants’
access to the information discovered
about their genomes is also a thorny issue
for researchers. Obligations need to be
negotiated in advance during the
informed-consent process, and must be in
place in situations when an individual is
found to have a particular abnormality in
his or her response to certain drugs, or
perhaps an increased risk of disease due to
a genetic susceptibility. 
“These are really difficult issues, and
you’ve  got to come up with solutions,”
says Manasco. “You can have the best sci-
ence in the world, but if your ethics aren’t
sound as well, and you haven’t carefully
thought about and addressed those issues,
it doesn’t matter. It isn’t something that is
a bother. This is the right thing to do.”
Impact on Health Care Costs
With pharmacogenomics innovations just
now starting to emerge, the jury is still out
on what effect they will ultimately have on
health care costs. How-
ever, most observers are
cautiously optimistic that
pharmacogenomics even-
tually will reduce costs.
Initially it may cost more
to run additional tests,
but as the practice be-
comes more common-
place, the actual benefits
of pharmacogenomics will
come into play, says Long.
“There’s up-front invest-
ment,” she says, “but ulti-
mately, if applied correct-
ly, in the right sort of
legal–social framework,
medical costs might not
necessarily go up, but may
even go down.” 
Ruaño echoes that
view. “I do believe that the
cost issue is going to be a chal-
lenge. However, it is really no dif-
ferent from any innovation in medical
technology,” he says. “Initially, it is going
to be expensive because it’s a first-genera-
tion product. The costs will decline, and it
will pay for itself in terms of efficacy to the
patient and reductions in side effects.” 
Hein is more sanguine on the issue.
“There’s no question in my mind that
ultimately you are going to save money
through pharmacogenetics,” he says. “It
makes perfect sense to me that health care
costs are going to come down—and hope-
fully rather substantially—with this type
of technology, because
there’s a lot of drug tox-
icity and a lot of drug
failure out there that
we  hope in the future
can be minimized.”
The issue will be
decided only when
answers to important
open questions are
found as events play out
in the coming years.
Will payers embrace
pharmacogenomic test-
ing and customized
drugs? Will drug com-
panies charge a premi-
um for new, targeted
therapies? Will patients
demand access to this
information and these
products, or will they be
leery? Will clinicians, who
are notably slow to adopt inno-
vations, educate themselves enough to
appreciate and effectively apply the new
decision-making tools of pharmacoge-
nomics? Will those of us alive today live to
see the dream of truly personalized medi-
cine for everyone come true? 
Ruaño is optimistic that we will. “I
think the history of technology has shown
us that many things we never expected to
be real really have moved very quickly,” he
says. “So watch for the data that are com-
ing out, watch out for publications and
associations of drugs. Once those are
established, the technology and the
approval and the acceptance will take care
of itself.”
Ernie Hood
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CYP450 Tests
The CYP450 family of enzymes is
the target of 60% of drugs today.
Companies are now marketing
CYP450 genotyping tests to physi-
cians and the public to help predict
optimal dose and drug efficacy.
The Future?
Pharmacogenomics
offers the hope of
using genetic profiling
to personalize—and
thereby improve—med-
ical treatment of a
variety of diseases,
including hypertension,
depression, cancer,
and HIV.